COVID-19 Impact on Non-prescription Drugs Market, Global Research Reports 2020-2021

Publisher Name :
Date: 27-May-2020
No. of pages: 109
Inquire Before Buying

This report covers market size and forecasts of Non-prescription Drugs, including the following market information:

Global Non-prescription Drugs Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)

Global Non-prescription Drugs Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)

Global Non-prescription Drugs Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)

Global Non-prescription Drugs Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)

Key market players

Major competitors identified in this market include Pfizer, Roche, Sanofi, Johnson & Johnson, Merck & Co. (MSD), Novartis, AbbVie, Gilead Sciences, GlaxoSmithKline (GSK), Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Teva, Bayer, Novo Nordisk, Allergan, Takeda, Boehringer Ingelheim, Takeda, etc.

Based on the Region:

Asia-Pacific (China, Japan, South Korea, India and ASEAN)

North America (US and Canada)

Europe (Germany, France, UK and Italy)

Rest of World (Latin America, Middle East & Africa)

Based on the Type:

Brand Drugs

Generic Drug

Based on the Application:

Hospital

Clinic

Other

COVID-19 Impact on Non-prescription Drugs Market, Global Research Reports 2020-2021

Table of Contents
1.1 Research Scope
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Non-prescription Drugs Industry
1.7 COVID-19 Impact: Non-prescription Drugs Market Trends
2 Global Non-prescription Drugs Quarterly Market Size Analysis
2.1 Non-prescription Drugs Business Impact Assessment - COVID-19
2.1.1 Global Non-prescription Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.1.2 Global Non-prescription Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Non-prescription Drugs Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
3.1 Global Non-prescription Drugs Quarterly Market Size by Manufacturers, 2019 VS 2020
3.2 Global Non-prescription Drugs Factory Price by Manufacturers
3.3 Location of Key Manufacturers Non-prescription Drugs Manufacturing Factories and Area Served
3.4 Date of Key Manufacturers Enter into Non-prescription Drugs Market
3.5 Key Manufacturers Non-prescription Drugs Product Offered
3.6 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Non-prescription Drugs Segments, By Type
4.1 Introduction
1.4.1 Brand Drugs
1.4.2 Generic Drug
4.2 By Type, Global Non-prescription Drugs Market Size, 2019-2021
4.2.1 By Type, Global Non-prescription Drugs Market Size by Type, 2020-2021
4.2.2 By Type, Global Non-prescription Drugs Price, 2020-2021
5 Impact of Covid-19 on Non-prescription Drugs Segments, By Application
5.1 Overview
5.5.1 Hospital
5.5.2 Clinic
5.5.3 Other
5.2 By Application, Global Non-prescription Drugs Market Size, 2019-2021
5.2.1 By Application, Global Non-prescription Drugs Market Size by Application, 2019-2021
5.2.2 By Application, Global Non-prescription Drugs Price, 2020-2021
6 Geographic Analysis
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Business Overview
7.1.2 Pfizer Non-prescription Drugs Quarterly Production and Revenue, 2020
7.1.3 Pfizer Non-prescription Drugs Product Introduction
7.1.4 Pfizer Response to COVID-19 and Related Developments
7.2 Roche
7.2.1 Roche Business Overview
7.2.2 Roche Non-prescription Drugs Quarterly Production and Revenue, 2020
7.2.3 Roche Non-prescription Drugs Product Introduction
7.2.4 Roche Response to COVID-19 and Related Developments
7.3 Sanofi
7.3.1 Sanofi Business Overview
7.3.2 Sanofi Non-prescription Drugs Quarterly Production and Revenue, 2020
7.3.3 Sanofi Non-prescription Drugs Product Introduction
7.3.4 Sanofi Response to COVID-19 and Related Developments
7.4 Johnson & Johnson
7.4.1 Johnson & Johnson Business Overview
7.4.2 Johnson & Johnson Non-prescription Drugs Quarterly Production and Revenue, 2020
7.4.3 Johnson & Johnson Non-prescription Drugs Product Introduction
7.4.4 Johnson & Johnson Response to COVID-19 and Related Developments
7.5 Merck & Co. (MSD)
7.5.1 Merck & Co. (MSD) Business Overview
7.5.2 Merck & Co. (MSD) Non-prescription Drugs Quarterly Production and Revenue, 2020
7.5.3 Merck & Co. (MSD) Non-prescription Drugs Product Introduction
7.5.4 Merck & Co. (MSD) Response to COVID-19 and Related Developments
7.6 Novartis
7.6.1 Novartis Business Overview
7.6.2 Novartis Non-prescription Drugs Quarterly Production and Revenue, 2020
7.6.3 Novartis Non-prescription Drugs Product Introduction
7.6.4 Novartis Response to COVID-19 and Related Developments
7.7 AbbVie
7.7.1 AbbVie Business Overview
7.7.2 AbbVie Non-prescription Drugs Quarterly Production and Revenue, 2020
7.7.3 AbbVie Non-prescription Drugs Product Introduction
7.7.4 AbbVie Response to COVID-19 and Related Developments
7.8 Gilead Sciences
7.8.1 Gilead Sciences Business Overview
7.8.2 Gilead Sciences Non-prescription Drugs Quarterly Production and Revenue, 2020
7.8.3 Gilead Sciences Non-prescription Drugs Product Introduction
7.8.4 Gilead Sciences Response to COVID-19 and Related Developments
7.9 GlaxoSmithKline (GSK)
7.9.1 GlaxoSmithKline (GSK) Business Overview
7.9.2 GlaxoSmithKline (GSK) Non-prescription Drugs Quarterly Production and Revenue, 2020
7.9.3 GlaxoSmithKline (GSK) Non-prescription Drugs Product Introduction
7.9.4 GlaxoSmithKline (GSK) Response to COVID-19 and Related Developments
7.10 Amgen
7.10.1 Amgen Business Overview
7.10.2 Amgen Non-prescription Drugs Quarterly Production and Revenue, 2020
7.10.3 Amgen Non-prescription Drugs Product Introduction
7.10.4 Amgen Response to COVID-19 and Related Developments
7.11 AstraZeneca
7.11.1 AstraZeneca Business Overview
7.11.2 AstraZeneca Non-prescription Drugs Quarterly Production and Revenue, 2020
7.11.3 AstraZeneca Non-prescription Drugs Product Introduction
7.11.4 AstraZeneca Response to COVID-19 and Related Developments
7.12 Bristol-Myers Squibb
7.12.1 Bristol-Myers Squibb Business Overview
7.12.2 Bristol-Myers Squibb Non-prescription Drugs Quarterly Production and Revenue, 2020
7.12.3 Bristol-Myers Squibb Non-prescription Drugs Product Introduction
7.12.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
7.13 Eli Lilly
7.13.1 Eli Lilly Business Overview
7.13.2 Eli Lilly Non-prescription Drugs Quarterly Production and Revenue, 2020
7.13.3 Eli Lilly Non-prescription Drugs Product Introduction
7.13.4 Eli Lilly Response to COVID-19 and Related Developments
7.14 Teva
7.14.1 Teva Business Overview
7.14.2 Teva Non-prescription Drugs Quarterly Production and Revenue, 2020
7.14.3 Teva Non-prescription Drugs Product Introduction
7.14.4 Teva Response to COVID-19 and Related Developments
7.15 Bayer
7.15.1 Bayer Business Overview
7.15.2 Bayer Non-prescription Drugs Quarterly Production and Revenue, 2020
7.15.3 Bayer Non-prescription Drugs Product Introduction
7.15.4 Bayer Response to COVID-19 and Related Developments
7.16 Novo Nordisk
7.16.1 Novo Nordisk Business Overview
7.16.2 Novo Nordisk Non-prescription Drugs Quarterly Production and Revenue, 2020
7.16.3 Novo Nordisk Non-prescription Drugs Product Introduction
7.16.4 Novo Nordisk Response to COVID-19 and Related Developments
7.17 Allergan
7.17.1 Allergan Business Overview
7.17.2 Allergan Non-prescription Drugs Quarterly Production and Revenue, 2020
7.17.3 Allergan Non-prescription Drugs Product Introduction
7.17.4 Allergan Response to COVID-19 and Related Developments
7.18 Takeda
7.18.1 Takeda Business Overview
7.18.2 Takeda Non-prescription Drugs Quarterly Production and Revenue, 2020
7.18.3 Takeda Non-prescription Drugs Product Introduction
7.18.4 Takeda Response to COVID-19 and Related Developments
7.19 Boehringer Ingelheim
7.19.1 Boehringer Ingelheim Business Overview
7.19.2 Boehringer Ingelheim Non-prescription Drugs Quarterly Production and Revenue, 2020
7.19.3 Boehringer Ingelheim Non-prescription Drugs Product Introduction
7.19.4 Boehringer Ingelheim Response to COVID-19 and Related Developments
7.20 Takeda
7.20.1 Takeda Business Overview
7.20.2 Takeda Non-prescription Drugs Quarterly Production and Revenue, 2020
7.20.3 Takeda Non-prescription Drugs Product Introduction
7.20.4 Takeda Response to COVID-19 and Related Developments
8 Supply Chain and Sales Channels Analysis
8.1 Non-prescription Drugs Supply Chain Analysis
8.1.1 Non-prescription Drugs Supply Chain Analysis
8.1.2 Covid-19 Impact on Non-prescription Drugs Supply Chain
8.2 Distribution Channels Analysis
8.2.1 Non-prescription Drugs Distribution Channels
8.2.2 Covid-19 Impact on Non-prescription Drugs Distribution Channels
8.2.3 Non-prescription Drugs Distributors
8.3 Non-prescription Drugs Customers
9 Key Findings
10 Appendix
10.1 About Us
10.2 Disclaimer
List of Tables

Table 1. Overview of the World Economic Outlook Projections
Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)
Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 7. Covid-19 Impact: Global Major Government Policy
Table 8. The Covid-19 Impact on Non-prescription Drugs Assessment
Table 9. COVID-19 Impact: Non-prescription Drugs Market Trends
Table 10. COVID-19 Impact Global Non-prescription Drugs Market Size
Table 11. Global Non-prescription Drugs Market Size Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (K Units)
Table 12. Global Non-prescription Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026, (USD/Unit)
Table 13. Global Non-prescription Drugs Quarterly Market Size, 2020 (US$ Million) & (K Units)
Table 14. Global Non-prescription Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million)
Table 15. Global Non-prescription Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (K Units)
Table 16. Global Non-prescription Drugs Market Growth Drivers
Table 17. Global Non-prescription Drugs Market Restraints
Table 18. Global Non-prescription Drugs Market Opportunities
Table 19. Global Non-prescription Drugs Market Challenges
Table 20. Key Manufacturers Non-prescription Drugs Quarterly Revenue, 2019 VS 2020 (US$ Million)
Table 21. Top Manufacturers, Non-prescription Drugs Market Size, 2019 (K Units) & (US$ Million)
Table 22. Non-prescription Drugs Factory Price by Manufacturers 2020 (USD/Unit)
Table 23. Location of Key Manufacturers Non-prescription Drugs Manufacturing Plants
Table 24. Key Manufacturers Non-prescription Drugs Market Served
Table 25. Date of Key Manufacturers Enter into Non-prescription Drugs Market
Table 26. Key Manufacturers Non-prescription Drugs Product Type
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Non-prescription Drugs Market Size by Type, 2020, (US$ Million)
Table 29. Global Non-prescription Drugs Market Size by Type, 2020 (K Units)
Table 30. Global Non-prescription Drugs Price: by Type, 2020-2021 (USD/Unit)
Table 31. Global Non-prescription Drugs Market Size by Application: 2020-2021 (US$ Million)
Table 32. Global Non-prescription Drugs Market Size by Application, 2020-2021 (K Units)
Table 33. Global Non-prescription Drugs Price: by Application, 2020-2021 (USD/Unit)
Table 34. Global Non-prescription Drugs Market Size by Region, 2019-2021 (US$ Million)
Table 35. Global Non-prescription Drugs Market Size by Region, 2019-2021 (K Units)
Table 36. By Country, North America Non-prescription Drugs Market Size, 2019-2021 (US$ Million)
Table 37. By Country, North America Non-prescription Drugs Market Size, 2019-2021 (K Units)
Table 38. US Non-prescription Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 39. Canada Non-prescription Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 40. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)
Table 41. By Country, Europe Non-prescription Drugs Market Size, 2019-2021 (US$ Million)
Table 42. By Country, Europe Non-prescription Drugs Market Size, 2019-2021 (K Units)
Table 43. Germany Non-prescription Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 44. France Non-prescription Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 45. UK Non-prescription Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 46. Italy Non-prescription Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 47. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)
Table 48. By Region, Asia-Pacific Non-prescription Drugs Market Size, 2019-2021 (US$ Million)
Table 49. By Region, Asia-Pacific Non-prescription Drugs Market Size, 2019-2021 (K Units)
Table 50. China Non-prescription Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 51. Japan Non-prescription Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 52. South Korea Non-prescription Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 53. India Non-prescription Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 54. ASEAN Non-prescription Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 55. Latin America Non-prescription Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 56. Middle East and Africa Non-prescription Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 57. Pfizer Business Overview
Table 58. Pfizer Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 59. Pfizer Non-prescription Drugs Product
Table 60. Pfizer Response to COVID-19 and Related Developments
Table 61. Roche Business Overview
Table 62. Roche Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 63. Roche Non-prescription Drugs Product
Table 64. Roche Response to COVID-19 and Related Developments
Table 65. Sanofi Business Overview
Table 66. Sanofi Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 67. Sanofi Non-prescription Drugs Product
Table 68. Sanofi Response to COVID-19 and Related Developments
Table 69. Johnson & Johnson Business Overview
Table 70. Johnson & Johnson Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 71. Johnson & Johnson Non-prescription Drugs Product
Table 72. Johnson & Johnson Response to COVID-19 and Related Developments
Table 73. Merck & Co. (MSD) Business Overview
Table 74. Merck & Co. (MSD) Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 75. Merck & Co. (MSD) Non-prescription Drugs Product
Table 76. Merck & Co. (MSD) Response to COVID-19 and Related Developments
Table 77. Novartis Business Overview
Table 78. Novartis Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 79. Novartis Non-prescription Drugs Product
Table 80. Novartis Response to COVID-19 and Related Developments
Table 81. AbbVie Business Overview
Table 82. AbbVie Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 83. AbbVie Non-prescription Drugs Product
Table 84. AbbVie Response to COVID-19 and Related Developments
Table 85. Gilead Sciences Business Overview
Table 86. Gilead Sciences Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 87. Gilead Sciences Non-prescription Drugs Product
Table 88. Gilead Sciences Response to COVID-19 and Related Developments
Table 89. GlaxoSmithKline (GSK) Business Overview
Table 90. GlaxoSmithKline (GSK) Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 91. GlaxoSmithKline (GSK) Non-prescription Drugs Product
Table 92. GlaxoSmithKline (GSK) Response to COVID-19 and Related Developments
Table 93. Amgen Business Overview
Table 94. Amgen Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 95. Amgen Non-prescription Drugs Product
Table 96. Amgen Response to COVID-19 and Related Developments
Table 97. AstraZeneca Business Overview
Table 98. AstraZeneca Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 99. AstraZeneca Non-prescription Drugs Product
Table 100. AstraZeneca Response to COVID-19 and Related Developments
Table 101. Bristol-Myers Squibb Business Overview
Table 102. Bristol-Myers Squibb Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 103. Bristol-Myers Squibb Non-prescription Drugs Product
Table 104. Bristol-Myers Squibb Response to COVID-19 and Related Developments
Table 105. Eli Lilly Business Overview
Table 106. Eli Lilly Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 107. Eli Lilly Non-prescription Drugs Product
Table 108. Eli Lilly Response to COVID-19 and Related Developments
Table 109. Teva Business Overview
Table 110. Teva Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 111. Teva Non-prescription Drugs Product
Table 112. Teva Response to COVID-19 and Related Developments
Table 113. Bayer Business Overview
Table 114. Bayer Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 115. Bayer Non-prescription Drugs Product
Table 116. Bayer Response to COVID-19 and Related Developments
Table 117. Novo Nordisk Business Overview
Table 118. Novo Nordisk Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 119. Novo Nordisk Non-prescription Drugs Product
Table 120. Novo Nordisk Response to COVID-19 and Related Developments
Table 121. Allergan Business Overview
Table 122. Allergan Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 123. Allergan Non-prescription Drugs Product
Table 124. Allergan Response to COVID-19 and Related Developments
Table 125. Takeda Business Overview
Table 126. Takeda Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 127. Takeda Non-prescription Drugs Product
Table 128. Takeda Response to COVID-19 and Related Developments
Table 129. Boehringer Ingelheim Business Overview
Table 130. Boehringer Ingelheim Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 131. Boehringer Ingelheim Non-prescription Drugs Product
Table 132. Boehringer Ingelheim Response to COVID-19 and Related Developments
Table 133. Takeda Business Overview
Table 134. Takeda Non-prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 135. Takeda Non-prescription Drugs Product
Table 136. Takeda Response to COVID-19 and Related Developments
Table 137. Non-prescription Drugs Distributors List
Table 138. Non-prescription Drugs Customers List
Table 139. Covid-19 Impact on Non-prescription Drugs Customers
List of Figures

Figure 1. Non-prescription Drugs Product Picture
Figure 2. Non-prescription Drugs Market Segmentation
Figure 3. Research Objectives
Figure 4. Research Process
Figure 5. Data Triangulation
Figure 6. Research Approach
Figure 7. Commodity Prices-Metals Price Indices
Figure 8. Commodity Prices- Precious Metal Price Indices
Figure 9. Commodity Prices- Agricultural Raw Material Price Indices
Figure 10. Commodity Prices- Food and Beverage Price Indices
Figure 11. Commodity Prices- Fertilizer Price Indices
Figure 12. Commodity Prices- Energy Price Indices
Figure 13. G20+: Economic Policy Responses to COVID-19
Figure 14. Global Non-prescription Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million)
Figure 15. Global Non-prescription Drugs Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)
Figure 16. Global Non-prescription Drugs Market Size, Quarterly Growth, 2020-2021 (%)
Figure 17. Global Non-prescription Drugs Market Size, Market Share by Type, 2019 VS 2020 (%)
Figure 18. Global Non-prescription Drugs Market Size, Market Share by Application, 2019 VS 2020 (%)
Figure 19. Global Non-prescription Drugs Market Size Market Share by Region, 2019 VS 2020 (%)
Figure 20. United States Composite PMI and GDP
Figure 21. Eurozone Composite PMI and GDP
Figure 22. Eurozone Core v. Periphery PMI Output Indices
Figure 23. Core v. Periphery PMI Employment Indices
Figure 24. UK Composite PMI and GDP
Figure 25. Caixin China Composite Output Index
Figure 26. Caixin China General Services Business Activity Index
Figure 27. Japan Composite Output Index
Figure 28. South Korea Manufacturing PMI
Figure 29. India Composite Output Index
Figure 30. ASEAN Manufacturing PMI
Figure 31. By Region, Asia-Pacific Non-prescription Drugs Market Size Market Share, 2019-2021
  • Global Human Adiponectin Antibody Market Growth 2020-2025
    Published: 03-Jul-2020        Price: US 3660 Onwards        Pages: 165
    According to this study, over the next five years the Human Adiponectin Antibody market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Human Adiponectin Antibody business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Human Adiponectin A......
  • Global Adiponectin Antibody Market Growth 2020-2025
    Published: 03-Jul-2020        Price: US 3660 Onwards        Pages: 165
    According to this study, over the next five years the Adiponectin Antibody market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Adiponectin Antibody business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Adiponectin Antibody market by ......
  • Global PECAM-1 Antibody Market Growth 2020-2025
    Published: 03-Jul-2020        Price: US 3660 Onwards        Pages: 175
    According to this study, over the next five years the PECAM-1 Antibody market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in PECAM-1 Antibody business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of PECAM-1 Antibody market by product type......
  • Global PECAM-1 Protein Market Growth 2020-2025
    Published: 03-Jul-2020        Price: US 3660 Onwards        Pages: 164
    According to this study, over the next five years the PECAM-1 Protein market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in PECAM-1 Protein business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of PECAM-1 Protein market by product type, a......
  • Global Human VEGF Antibody Market Growth 2020-2025
    Published: 03-Jul-2020        Price: US 3660 Onwards        Pages: 182
    According to this study, over the next five years the Human VEGF Antibody market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Human VEGF Antibody business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Human VEGF Antibody market by pro......
  • Global VEGF Antibody Market Growth 2020-2025
    Published: 03-Jul-2020        Price: US 3660 Onwards        Pages: 178
    According to this study, over the next five years the VEGF Antibody market will register a XX%% CAGR in terms of revenue, the global market size will reach $ XX million by 2025, from $ XX million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in VEGF Antibody business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of VEGF Antibody market by product type, applica......
  • Global OTC Vitamins and Minerals Dietary Supplement Market Growth (Status and Outlook) 2020-2025
    Published: 03-Jul-2020        Price: US 3660 Onwards        Pages: 139
    According to this study, over the next five years the OTC Vitamins and Minerals Dietary Supplement market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global revenue market share of key companies in OTC Vitamins and Minerals Dietary Supplement business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunitie......
  • Global Essential Oils and Plant Extracts for Livestock Market Growth (Status and Outlook) 2020-2025
    Published: 03-Jul-2020        Price: US 3660 Onwards        Pages: 118
    According to this study, over the next five years the Essential Oils and Plant Extracts for Livestock market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Essential Oils and Plant Extracts for Livestock business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opport......
  • Global Oral Ulcer Drug Market Insights and Forecast to 2026
    Published: 02-Jul-2020        Price: US 3900 Onwards        Pages: 115
    Oral Ulcer Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Oral Ulcer Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026. Segment by Type, the Oral Ulcer Drug market is segmented into - Antihistamine - Antibacterial - Corticosteroid and Ana......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs